ArticleBMC cancer2025
Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients.Translational oncology · 2026Article
- Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBladder cancer (BLCA) is a highly heterogeneous malignancy with high morbidity and mortality. Massive lactate production and hypoxia are characteristics of the tumor microenvironment (TME). However, our understanding of the clinical value of hypoxia and lactate metabolism (HLM) in BLCA remains limited.
methodsK-means clustering algorithm was used to classify molecular subtypes. The prognostic model was developed via univariate cox regression, random forest, and stepwise multivariate cox regression analyses. We subsequently systematically correlated the hypoxia and lactate metabolism-related risk score with the TME, BLCA consensus subtypes, and potential predictive value for drug therapy efficacy. Single-cell analyses demonstrated the expression of the modeling genes in various cell subtypes in the TME, and experimental validation was performed to examine the expression and function of GALK1 and TFRC.
resultsThe TCGA cohort was classified into two subtypes. A 9-gene signature was established on the basis of genes associated with HLM, which predicted prognosis with exceptional efficacy. Patients with high risk scores had a poor prognosis, abundant infiltration of tumor-promoting immune cells and suppressed immune function. Furthermore, we anticipated that these patients were insensitive to immunotherapy and conventional chemotherapeutic agents. In addition, such patients were more inclined to the basal subtype. The modeling genes GALK1 and TFRC were highly expressed in BLCA and promoted tumor cell proliferation and migration.
conclusionsOur signature further illustrated heterogeneity of BLCA. This signature could predict prognosis, consensus subtypes and treatment efficacy. We believe that this signature can optimize individual treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.